Literature DB >> 12114798

Midgut Carcinoids and Solid Carcinomas of the Intestine: Differences in Endocrine Markers and p53 Mutations.

Peder Weckstrom, Anders Hedrum, Charlie Makridis, Goran Akerstrom, Jonas Rastad, Lena Scheibenpflug, Mattias Uhlen, Claes Juhlin, Erik Wilander.   

Abstract

Fifteen midgut carcinoid tumors and 5 solid carcinomas of the intestine with carcinoid-like morphological features were evaluated histochemically and immunohistochemically with respect to various endocrine markers and expression of mutant p53 protein. Direct sequencing of the p53 gene after PCR amplification was carried out on microdissected cells from all tumors. All investigated carcinoid tumors showed chromogranin and argentaffin reaction, but lacked nuclear immunostaining with p53 antibodies. In 14 immunohistochemically negative midgut carcinoid tumors, no mutations were identified. One carcinoid tumor devoid of p53 staining was, however, found to contain mutation in exon 6 of the p53 gene. In contrast, the solid carcinomas were essentially chromogranin negative but all displayed clearly positive p53 staining in a variable number of cell nuclei. Sequence analysis of exons 5-8 of the p53 gene in the 5 carcinomas showed mutations in exons 6 and 7 in 2 tumors and in exon 8 in 2 other tumors, while no mutation was detected in the fifth tumor. The carcinoid tumors and the solid carcinomas of the small intestine are thought to derive histogenetically from endocrine cells and enterocytes, respectively. The present results substantiate that divergent mechanisms operate in the development of the two tumor types.

Entities:  

Year:  1996        PMID: 12114798     DOI: 10.1007/bf02739834

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  20 in total

1.  A MODIFICATION OF THE MASSON-HAMPERL METHOD FOR STAINING OF ARGENTAFFIN CELLS.

Authors:  I SINGH
Journal:  Anat Anz       Date:  1964-07-31

2.  Bidirectional solid-phase sequencing of in vitro-amplified plasmid DNA.

Authors:  T Hultman; S Bergh; T Moks; M Uhlén
Journal:  Biotechniques       Date:  1991-01       Impact factor: 1.993

3.  Direct solid phase sequencing of genomic and plasmid DNA using magnetic beads as solid support.

Authors:  T Hultman; S Ståhl; E Hornes; M Uhlén
Journal:  Nucleic Acids Res       Date:  1989-07-11       Impact factor: 16.971

Review 4.  Clinical implications of the p53 tumor-suppressor gene.

Authors:  C C Harris; M Hollstein
Journal:  N Engl J Med       Date:  1993-10-28       Impact factor: 91.245

5.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

6.  Detection of p53 overexpression in routinely paraffin-embedded tissue of human carcinomas using a novel target unmasking fluid.

Authors:  F M van den Berg; I O Baas; M M Polak; G J Offerhaus
Journal:  Am J Pathol       Date:  1993-02       Impact factor: 4.307

7.  An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53.

Authors:  B Vojtĕsek; J Bártek; C A Midgley; D P Lane
Journal:  J Immunol Methods       Date:  1992-07-06       Impact factor: 2.303

8.  Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium.

Authors:  M Ramael; G Lemmens; C Eerdekens; C Buysse; I Deblier; W Jacobs; E van Marck
Journal:  J Pathol       Date:  1992-12       Impact factor: 7.996

9.  Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli.

Authors:  C A Midgley; C J Fisher; J Bártek; B Vojtĕsek; D Lane; D M Barnes
Journal:  J Cell Sci       Date:  1992-01       Impact factor: 5.285

10.  Frequent genetic instability in small intestinal carcinomas.

Authors:  K Hibi; K Kondo; S Akiyama; K Ito; H Takagi
Journal:  Jpn J Cancer Res       Date:  1995-04
View more
  3 in total

1.  Gene Amplifications in Well-Differentiated Pancreatic Neuroendocrine Tumors Inactivate the p53 Pathway.

Authors:  Wenwei Hu; Zhaohui Feng; Ippolito Modica; David S Klimstra; Lin Song; Peter J Allen; Murray F Brennan; Arnold J Levine; Laura H Tang
Journal:  Genes Cancer       Date:  2010-05-15

2.  A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum.

Authors:  Kyle M Walsh; Murim Choi; Kjell Oberg; Matthew H Kulke; James C Yao; Chengqing Wu; Magdalena Jurkiewicz; Ling-I Hsu; Susanne M Hooshmand; Manal Hassan; Eva T Janson; Janet L Cunningham; Evan Vosburgh; Richard S Sackler; Richard P Lifton; Andrew T Dewan; Josephine Hoh
Journal:  Endocr Relat Cancer       Date:  2011-01-13       Impact factor: 5.678

3.  Biology and treatment of metastatic gastrointestinal neuroendocrine tumors.

Authors:  Jonathan R Strosberg; Aejaz Nasir; Pamela Hodul; Larry Kvols
Journal:  Gastrointest Cancer Res       Date:  2008-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.